Complete financial analysis of Longboard Pharmaceuticals, Inc. (LBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Longboard Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rothschild & Co SCA (PIEJF) Income Statement Analysis – Financial Results
- Vinda International Holdings Limited (VDAHF) Income Statement Analysis – Financial Results
- Ebro Foods, S.A. (EBRPF) Income Statement Analysis – Financial Results
- Basin Uranium Corp. (NCLR.CN) Income Statement Analysis – Financial Results
- Daikin Industries,Ltd. (DKILY) Income Statement Analysis – Financial Results
Longboard Pharmaceuticals, Inc. (LBPH)
About Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 5.00K | 1.00K | 0.00 |
| Gross Profit | -5.00K | -5.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.75M | 34.64M | 19.77M | 4.63M |
| General & Administrative | 13.01M | 10.16M | 8.07M | 9.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.01M | 10.16M | 8.07M | 9.77M |
| Other Expenses | 0.00 | 16.00K | -22.00K | 0.00 |
| Operating Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Cost & Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Interest Income | 2.41M | 837.00K | 64.00K | 0.00 |
| Interest Expense | 0.00 | 837.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 5.00K | 1.00K | 7.00M |
| EBITDA | -56.75M | -44.79M | -27.84M | -14.40M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -56.76M | -44.80M | -27.84M | -14.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | 853.00K | 42.00K | 0.00 |
| Income Before Tax | -54.42M | -43.95M | -27.80M | -14.40M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -853.00K | -64.00K | -14.40K |
| Net Income | -54.42M | -43.09M | -27.73M | -14.40M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.39 | -2.51 | -1.62 | -0.82 |
| EPS Diluted | -2.39 | -2.51 | -1.62 | -0.82 |
| Weighted Avg Shares Out | 22.73M | 17.15M | 17.07M | 17.67M |
| Weighted Avg Shares Out (Dil) | 22.73M | 17.15M | 17.07M | 17.67M |
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares.
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
This biotech stock has surged over 300% this week
As the market continues to witness a resurgence in small-cap investments, led by a jump in investor optimism and speculation, there's been a seemingly steady flow of capital back into traditionally riskier sectors.
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common...
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to...
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
Clinical-stage biopharmaceutical firm Longboard Pharmaceuticals (NASDAQ: LBPH ) got the new year off to the best start possible with a dramatic run. Earlier Tuesday morning, management disclosed positive topline data for its therapeutic bexicaserin, which addresses seizures in patients with...
Longboard Pharmaceuticals stock soars on seizure drug results
Longboard Pharmaceuticals Inc shares surged 181% to $16.96 in late-morning trading on Tuesday after the clinical-stage biopharmaceutical company revealed positive topline data from its PACIFIC Study evaluating bexicaserin, which reduced seizures by 53.3% across a population of patients with developmental...
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #DEEs--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly...
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study,...
Source: https://incomestatements.info
Category: Stock Reports